메뉴 건너뛰기
The Lancet
Volumn 376, Issue 9754, 2010, Pages 1736-
Trastuzumab for gastric cancer treatment
Author keywords

[No Author keywords available]
Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;
EID: 78649337579     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)62127-7     Document Type: Letter
Times cited : (10)
References (5)
  • 1
    • 77956268693 scopus 로고    scopus 로고
    • Cancer research in the global village
    • AJ Munro, PG Niblock Cancer research in the global village Lancet 376 2010 659 660
    • (2010) Lancet , vol.376 , pp. 659-660
    • Munro, A.J.1    Niblock, P.G.2
  • 2
    • 77956262693 scopus 로고    scopus 로고
    • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
    • YJ Bang, E Van Cutsem, A Feyereislova Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
    • (2010) Lancet , vol.376 , pp. 687-697
    • Bang, Y.J.1    Van Cutsem, E.2    Feyereislova, A.3
  • 3
    • 77954216167 scopus 로고    scopus 로고
    • Quality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer
    • Jan 22-24 Orlando, FL, USA; abstr 7
    • Satoh T, Loen J, Lopez RI, et al. Quality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. Gastrointestinal Cancers Symposium; Jan 22-24, 2010; Orlando, FL, USA; abstr 7.
    • (2010) Gastrointestinal Cancers Symposium
    • Satoh, T.1    Loen, J.2    Lopez, R.I.3
  • 4
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • DJ Slamon, B Leyland-Jones, S Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 5
    • 33845914783 scopus 로고    scopus 로고
    • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial
    • I Smith, M Procter, RD Gelber 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 396 2007 29 36
    • (2007) Lancet , vol.396 , pp. 29-36
    • Smith, I.1    Procter, M.2    Gelber, R.D.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.